Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) EPS (Weighted Average and Diluted) (2024 - 2026)

Beta Bionics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at -$0.49 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 47.31% to -$0.49 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.5, a 80.0% increase, with the full-year FY2025 number at -$1.81, up 78.95% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.49 in Q1 2026 for Beta Bionics, down from -$0.29 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for BBNX hit a ceiling of -$0.29 in Q4 2025 and a floor of -$2.74 in Q4 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$1.23 across 3 years, with a median of -$0.93 in 2025.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 89.42% in 2025 and later soared 47.31% in 2026.
  • Tracing BBNX's EPS (Weighted Average and Diluted) over 3 years: stood at -$2.74 in 2024, then soared by 89.42% to -$0.29 in 2025, then tumbled by 68.97% to -$0.49 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BBNX at -$0.49 in Q1 2026, -$0.29 in Q4 2025, and -$0.33 in Q3 2025.